News

Kappa says K2VITAL DELTA proven to be stable

Kappa Bioscience has announced that its K2VITAL DELTA, a double-coated and microencapsulated form of vitamin K2 MK-7, is now stability tested and shown to remain stable in challenging conditions, providing freedom for product formulations. This, according to the company, offers unique possibilities for product development, especially for the growing bone and heart health markets. A year-long […]

Kappa Bioscience has announced that its K2VITAL DELTA, a double-coated and microencapsulated form of vitamin K2 MK-7, is now stability tested and shown to remain stable in challenging conditions, providing freedom for product formulations. This, according to the company, offers unique possibilities for product development, especially for the growing bone and heart health markets.

A year-long stability test on K2VITAL DELTA is said to confirm that the product remains stable throughout shelf-life even in tough conditions, e.g. when combined with minerals. After 12 months of testing at 25 0C, Kappa says that K2VITAL DELTA lost less than 4 % of its original activity, and at 40 0C it was 86 % recovered. The strong stability is attributed to its double-coated microencapsulated form.

Stability issues are a common challenge for formulations containing non-microencapsulated fat-soluble vitamins, Kappa claims, leading to finished products not containing as much vitamin as claimed on the label, noting that  K2VITAL DELTA is the only vitamin K2 MK-7 available on the market in a microencapsulated form.

“The proven stability of K2VITAL DELTA provides a unique freedom for product developers when choosing the desired product format and formulations with vitamin K2 MK-7,” said Egil Greve, CEO of Kappa Bioscience. “It also means greater cost-effectiveness, as significantly less overage is required to secure the declared content on the label throughout the shelf-life.”

“K2VITAL DELTA is the fastest growing variant in our K2VITAL portfolio, with sales volume growing by over 500 % since April 2014. This clearly shows the rapid development of the K2 segment and the market need for a stable and pure vitamin K2 MK-7,” continued Greve. “Our estimate is that the vitamin K2 segment will experience a CAGR of approximately 50 % in retail value over the next 5 years.”

Kappa says that the most prominent application categories for vitamin K2 at the moment are bone and heart health, with the consumer product markets for these on a clear growth trajectory, aided by several factors, such as population ageing and increasing holistic interest in health. As both of these markets are well-established and even crowded, finding ways to differentiate formulations and reach new target consumer groups is crucial to staying competitive, the company claims, saying that. K2VITALDELTA offers interesting opportunities to add or create new valuable benefits for consumers.